Journey Medical Corp (DERM)

$1.25 0.09 (7.76%)

15:59 EDT DERM Stock Quote Delayed 30 Minutes

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

By William White, InvestorPlace Writer May 22, 2023

We're starting off the week with a breakdown of the biggest pre-market stock movers traders need to know about on Monday!

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

7 Investing Resolutions to Follow in 2020

5 Growthy Biotech Stocks to Buy Despite the Scrutiny

More Articles

Volume:

Previous Close -

Market Cap 68.15M

PE Ratio -0.40

EPS -3.09

Volume (Avg. Vol.) 12,903

Day's Range $1.14 - $1.27

52-Week Range $1.02 - $4.36

Dividend & Yield N/A (N/A)

DERM Stock Predictions, Articles, and Journey Medical Corp News

From InvestorPlace
From the Web

Dermira News: Why DERM Stock Is Skyrocketing Today

By William White, InvestorPlace Writer Mar 18, 2019

Dermira news concerning positive results from a recent Phase 2b study of lebrikizumab has DERM stock flying high on Monday.

5 Big Biotech Stocks to Buy Under $10

By Aaron Levitt, InvestorPlace Contributor Mar 20, 2018

Small biotech stocks can pack a wallop. Here are five biotech stocks that have prospects bigger than their share prices.

Dermira Inc Stock Plunges on Acne Drug Failure

By William White, InvestorPlace Writer Mar 5, 2018

Dermira (DERM) stock is tanking today on news that its new acne drug is a failure and that it will likely stop its development.

10 Pharmaceuticals Stocks to Sell Now

By Portfolio Grader Dec 23, 2016

This week, the overall grades of 10 Pharmaceuticals stocks are lower, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").

10 Pharmaceuticals Stocks to Buy Now

By Portfolio Grader Oct 7, 2016

10 Pharmaceuticals stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an "A" ("strong buy") or "B" overall ("buy").

11 Pharmaceuticals Stocks to Buy Now

By Portfolio Grader Sep 30, 2016

The grades of 11 Pharmaceuticals stocks are on the rise this week on Portfolio Grader. Each of these stocks is rated an "A" ("strong buy") or "B" overall ("buy").

Biggest Movers in Manufacturing Stocks Now – ACUR NVET AEPI SJM

By Portfolio Grader Jun 9, 2016

The following stocks were moving the Manufacturing sector today.

3 Stocks to Watch on Thursday: Ciena Corporation (CIEN), Dermira Inc (DERM) and Joy Global Inc. (JOY)

By Karl Utermohlen, InvestorPlace Writer Jun 2, 2016

Ciena (CIEN) and Joy Global (JOY) shoot higher on Street-beating results, while Dermira (DERM) is popping on positive trial news for its sweating treatment.

Biggest Movers in Manufacturing Stocks Now – CCXI CROX NLS DERM

By Portfolio Grader May 10, 2016

The Manufacturing sector saw plenty of trading activity today, including the following leaders and losers.

3 Biotech Stocks You’ll Love Betting Against: FPRX, DERM, AGTC

By Profit Scanner Feb 19, 2016

Bearish investors can find an opportunity in these biotech stocks as they look to continue a downward trend.

66 Biggest Movers From Friday

From Benzinga May 23, 2022

Gainers GeoVax Labs, Inc. (NASDAQ: GOVX) shares surged 90.2% to settle at $1.39 on Friday. GeoVax Labs, last month, said its Q1 sales results were lower year over year.

Earnings Scheduled For March 23, 2022

From Benzinga Mar 23, 2022

Companies Reporting Before The Bell • AYRO (NASDAQ:AYRO) is expected to report earnings for its fourth quarter. • First Trust NASDAQ Clean Edge Smart Grid...

B.Riley Financial Sticks to Their Buy Rating for Journey Medical Corp (DERM)

From TipRanks Jan 13, 2022

B.Riley Financial analyst Kalpit Patel

B.Riley Financial Sticks to Its Buy Rating for Journey Medical Corp (DERM)

From TipRanks Dec 21, 2021

In a report released today, Kalpit Pate...

A Powerful Buy Signal

From Talk Markets Sep 12, 2020

Phase 2 trials are my favorite time to get involved in a biotech company. Phase 2 is often the most profitable time to be involved in a small cap biotech stock. Many times, Phase 2 results are positive.

Benzinga's Top Ratings Upgrades, Downgrades For February 25, 2022

From Benzinga Feb 25, 2022

Upgrades According to 86 Research, the prior rating for NetEase Inc (NASDAQ:NTES) was changed from Hold to Buy. For the fourth quarter, NetEase had an EPS of $1.56,...